SurveyMonkey parent SVMK (NASDAQ:SVMK) enjoyed a successful IPO last week, with shares closing out the first day of trading 44% higher than the offering price. SurveyMonkey also announced that its underwriters exercised all of their options, purchasing an additional 2.25 million shares at $12. That was quite a bit of hype for a maker of survey software.
However, investor enthusiasm has chilled in the days since, and the stock has started to come back down to Earth. Here are three reasons to stay away after the pop.
Image source: Getty Images.
Growth is slowingFor starters, SurveyMonkey's growth leaves a bit to be desired, both in terms of revenue and paying users. Sales grew 6% in 2017, and the company added just 10,000 paying users in the first half of 2018, ending the second quarter with 616,000 paying users. SurveyMonkey had 575,000 paying users at the end of 2016, meaning it took 18 months to add 41,000 paying users.
Top 10 Clean Energy Stocks To Buy For 2021: Extra Space Storage Inc(EXR)
Extra Space Storage, Inc. operates as a real estate investment trust (REIT) in the United States. It engages in property management and development activities that include acquiring, managing, developing, and selling, as well as the rental of self-storage facilities. As of December 31, 2006, Extra Space Storage owned interests in 567 properties located in 32 states and Washington, D.C., as well as managed 74 properties owned by franchisees or third parties. As a REIT, the company would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 1977 and is based in Salt Lake City, Utah.
There are a handful of REITs in the public storage sector that are worth a look, including Public Storage (NYSE: PSA), Cubesmart (NYSE: CUBE), National Storage Affiliates (NYSE: NSA), and Extra Space Storage (NYSE: EXR). Extra Space Storage, Inc. (NYSE:EXR) CFO P Scott Stubbs sold 15,600 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $98.58, for a total value of $1,537,848.00. Following the completion of the transaction, the chief financial officer now owns 160,612 shares of the company’s stock, valued at $15,833,130.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Panasonic (OTCMKTS:PCRFY) was downgraded by equities researchers at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Thursday. However, Panasonic (OTCPK:PCRFY) announced this week that it was happy to consider further investment in the Nevada facility. A similar move in China is not unlikely. Tesla expects to triple its energy storage business this year but its problem has been getting supply to meet the demand. Panasonic's announcement is probably connected to a very substantial energy storage contract win just announced by the company. ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of Ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber's congenital amaurosis (LCA). The Company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. The Company's product candidates include QR-010 and QR-110. The Company is focusing on developing QRX- 911, QRX- 021, QRX- 313 for Epidermolysis bullosa, QRX- 704 for Huntington's disease, QRX- 812, QRX- 411 for Usher syndrome, QRX- 504 for Fuchs, QRX- 604 for Friedreich's ataxia and QRX- 203 for Alzheimer's disease. QR-010 The Company's lead product candidate, QR-010, is an RNA-based oligonucleotide. QR-010 is designed to address the underlying cause of the disease by repairing the mRNA defect encoded by the delta-F508 mutation in the Cystic fibrosis transmembrane conductance regulator (CFTR) gene of CF patients. The delta-F508 mutation is a deletion of over three of the coding base pairs or nucleotides, in the CFTR gene, which results in the production of a misfolded CFTR protein that does not function normally. QR-110 is designed to bind to the mutated location in the pre-mRNA, thereby leading to normally spliced or wild-type mRNA, which could produce wild-type or normal protein. QR-110 is designed to be administered through intravitreal injections in the eye. QR-110 The Company's product candidate, QR-110, is an oligonucleotide. QR-110 is designed to treat the disease by repairing the underlying cause in the mRNA, which results in the production of wi! ld-type centrosomal protein 290 (CEP290 protein). QR-110 is designed to bind to the mutated location in the pre-mRNA, masking the cryptic splice site, thereby leading to normally spliced or wild-type mRNA, which could produce wild-type or normal protein. QR-110 is designed to be administered through intravitreal injections in the eye. The Company competes with Vertex Pharmaceuticals Inc., Novartis International AG, Hoffmann-LaRoche Ltd., Pfizer Inc., Galapagos, AbbVie Laboratories, Shire, Sanofi, Bayer AG, Proteostasis, Corbus Pharmaceuticals, Nivalis and Gilead. ProQR (NASDAQ:PRQR) is developing QR-110 to treat patients with a mutation on the same gene as EDIT-101 but in a much different manner. QR-110 would require repeat injections right in the eyes to help a mutated gene produce functional copies of the CEP290 protein, while EDIT-101 is designed to repair the gene and provide a permanent solution with a single treatment. Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) were up 16% as of 3:48 p.m. EDT on Monday. ProQR didn't report any new announcements, but the biotech's update last Wednesday from a phase 1/2 clinical study -- of RNA medicine QR-110, in treating Leber congenital amaurosis type 10 (LCA10) -- still had investors fired up. Cotiviti (NYSE:COTV) and FleetCor Technologies (NYSE:FLT) are both business services companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations. Shares of Cotiviti Holdings Inc. (NYSE:COTV) were up 10.2% as of 1:00 p.m. EDT Tuesday after Veritas Capital agreed to acquire the healthcare payment solutions company. Cotiviti Holdings, Inc. (NYSE:COTV) – Equities research analysts at Jefferies Group lowered their FY2018 earnings estimates for Cotiviti in a report issued on Wednesday, May 2nd. Jefferies Group analyst S. Dodge now expects that the business services provider will post earnings per share of $1.68 for the year, down from their previous estimate of $1.71. Jefferies Group also issued estimates for Cotiviti’s FY2019 earnings at $1.87 EPS. Reaves Utility Income Fund (the Fund) is a non-diversified, closed-end management investment company. The Fund's investment objective is to provide dividend income and capital appreciation. W.H. Reaves & Co., Inc. (Reaves) serves as the Fund's investment adviser. ALPS serves as the Fund's administrator. The Fund intends to invest at least 80% of its total assets in dividend-paying common and preferred stocks, and debt instruments of companies within the utility industry. The remaining 20% of its assets may be invested in other securities, including stocks, money market instruments and debt instruments, as well as certain derivative instruments in the utility industry or other industries. During the fiscal year ended October 31, 2005 (fiscal 2005), the common stock of electric utilities averaged about 47% of the Fund's portfolio. The telephone sector, particularly rural telecom, was a significant source of dividend income for the Fund, with an average yield of 5.75% in fiscal 2005. Telecommunications common holdings averaged about 19% of the Fund's portfolio during fiscal 2005. Preferred stock holdings, yielding 6.9%, accounted for 8.5% of the Fund's portfolio as of October 31, 2005. The top five holdings of the Fund, as of October 31, 2005, were Duke Energy (7.1%), Ameren Corporation (5.8%), Altria Group (5.4%), Great Plains Energy (5.1%) and AT&T (4.1%). Shares of UNITE Group plc (LON:UTG) have been given a consensus rating of “Hold” by the six brokerages that are covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is GBX 878.75 ($11.45). Or they can opt for a closed-end fund (CEF), like Wells Fargo Utilities and High Income Fund (NYSE: ERH) or Reaves Utility Income Fund (NYSE: UTG). Both deliver yields much higher than the 3.6% yield of XLU. Most recently, ERH was yielding 7.2% and UTG was yielding 6.7% thanks to the use of leverage. Liberum Capital restated their buy rating on shares of UNITE Group (LON:UTG) in a research note released on Friday morning. UTG has been the topic of a number of other reports. Peel Hunt restated a buy rating and issued a GBX 870 ($11.58) price target on shares of UNITE Group in a research report on Tuesday, February 27th. Morgan Stanley raised their price target on shares of UNITE Group from GBX 710 ($9.45) to GBX 850 ($11.32) and gave the stock an equal weight rating in a research report on Tuesday, March 13th. Numis Securities restated a restricted rating and issued a GBX 892 ($11.88) price target on shares of UNITE Group in a research report on Wednesday, February 21st. Finally, JPMorgan Chase & Co. raised their price target on shares of UNITE Group from GBX 850 ($11.32) to GBX 900 ($11.98) and gave the stock a neutral rating in a research report on Wednesday, March 7th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of GBX 862.83 ($11.49). We are a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system, or CNS, diseases. Leveraging our scientific insights and clinical experience, we have acquired or in-licensed four development-stage proprietary compounds that we believe have innovative mechanisms of action and therapeutic profiles that can potentially address the unmet needs of patients with these diseases. Our product portfolio and potential indications include: MIN-101 for the treatment of schizophrenia; MIN-202 (also known as JNJ-42847922), which we are co-developing with Janssen Pharmaceutica NV, or Janssen, for the treatment of insomnia disorder and adjunctive major depressive disorder, or MDD; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease. Advisors' Opinion: Minerva Neurosciences Inc (NASDAQ:NERV)Q4 2018 Earnings Conference CallMarch 12, 2019, 8:30 a.m. ET Operator AnaptysBio (NASDAQ: NERV) and Minerva Neurosciences (NASDAQ:NERV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Minerva Neurosciences (NASDAQ:NERV) was upgraded by analysts at BidaskClub from a hold rating to a buy rating. Nuvectra (NASDAQ:NVTR) was upgraded by analysts at BidaskClub from a hold rating to a buy rating. We were formed as GHL Acquisition Corp., a special purpose acquisition company, in November 2007, for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination. On February 21, 2008, we consummated our initial public offering. On September 29, 2009, we acquired, directly and indirectly, all the outstanding equity of Iridium Holdings LLC, or Iridium Holdings, and changed our name from GHL Acquisition Corp. to Iridium Communications Inc. Iridium Holdings was formed under the laws of Delaware in 2000, and on December 11, 2000, Iridium Holdings, through its wholly owned subsidiary Iridium Satellite LLC, or Iridium Satellite, acquired certain satellite assets from Iridium LLC, a non-affiliated debtor in possession, pursuant to an asset purchase agreement. Advisors' Opinion: We've tasked three of our Motley Fool contributors with finding three out-of-the-way stocks that Wall Street is overlooking and they've identified Iridium Communications (NASDAQ:IRDM)(NASDAQ:IRDMB), Winnebago (NYSE:WGO), and Five Below (NASDAQ:FIVE) as possibilities. Lincoln National Corporation, through its subsidiaries, engages in multiple insurance and retirement businesses in the United States. It operates through four segments: Annuities, Retirement Plan Services, Life Insurance, and Group Protection. The company sells a range of wealth protection, accumulation, and retirement income products and solutions. Its products include fixed and indexed annuities, variable annuities, universal life insurance (UL), variable universal life insurance (VUL), linked-benefit UL, term life insurance, indexed universal life insurance, and employer-sponsored retirement plans and services, as well as group life, disability, and dental products. Lincoln National Corporation also provides various plan investment vehicles, including individual and group variable annuities, group fixed annuities, and mutual fund-based programs; single and survivorship versions of UL and VUL, including corporate-owned UL and VUL, and bank-owned UL and VUL insurance products; and group non-medical insurance products, principally term life, universal life, disability, dental, vision, accident, and critical illness insurance to the employer market place through various forms of contributory and non-contributory plans. The company distributes its products through consultants, brokers, planners, agents, financial advisors, third-party administrators, and other intermediaries. Lincoln National Corporation was founded in 1904 and is headquartered in Radnor, Pennsylvania. LNC has been the subject of a number of analyst reports. ValuEngine lowered Lincoln National from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 24th. Bank of America cut their price target on Lincoln National from $79.00 to $75.00 and set a “buy” rating for the company in a research note on Friday, November 2nd. Keefe, Bruyette & Woods upgraded Lincoln National from a “market perform” rating to an “outperform” rating and set a $80.00 price target for the company in a research note on Monday, November 5th. Deutsche Bank cut their price target on Lincoln National from $74.00 to $73.00 and set a “buy” rating for the company in a research note on Monday, November 5th. Finally, Morgan Stanley cut their price target on Lincoln National from $76.00 to $74.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 13th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the company. Lincoln National presently has a consensus rating of “Hold” and a consensus price target of $74.69. Lincoln National Company Profile Lincoln National Co. (NYSE:LNC) shares gapped down before the market opened on Thursday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $69.98, but opened at $67.66. Lincoln National shares last traded at $65.70, with a volume of 3183810 shares. Lincoln National (NYSE:LNC)‘s stock had its “buy” rating reaffirmed by analysts at Royal Bank of Canada in a report issued on Friday. They currently have a $82.00 price target on the financial services provider’s stock. Royal Bank of Canada’s price objective points to a potential upside of 24.81% from the stock’s current price. The New Ireland Fund, Inc. (the Fund), incorporated on December 14, 1989, is a non-diversified, closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment primarily in equity securities of Irish companies. The Fund is designed for United States and other investors who wish to participate in the Irish securities markets. The Fund will invest at least 80% of its total assets in equity and fixed-income securities of Irish companies. To the extent that the balance of the Fund's assets is not so invested, it will have the flexibility to invest the remaining assets in non-Irish companies that are listed on a stock exchange. The Fund may invest up to 25% of its assets in equity securities that are not listed on any securities exchange. It invests in various sectors, including construction and building materials, financial, food and beverages, and healthcare services. The Fund's investment advisor is Bank of Ireland Asset Management (U.S.) Limited. The New Ireland Fund, Inc. (NYSE:IRL) Director Margaret Duffy acquired 2,000 shares of the business’s stock in a transaction that occurred on Monday, October 8th. The stock was bought at an average cost of $9.85 per share, for a total transaction of $19,700.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. IrishCoin (CURRENCY:IRL) traded 1.6% lower against the US dollar during the 1-day period ending at 10:00 AM E.T. on October 7th. During the last week, IrishCoin has traded 6% lower against the US dollar. IrishCoin has a market cap of $167,948.00 and $146.00 worth of IrishCoin was traded on exchanges in the last 24 hours. One IrishCoin coin can currently be purchased for about $0.0047 or 0.00000071 BTC on exchanges. Media headlines about The New Ireland Fund (NYSE:IRL) have been trending somewhat positive on Saturday, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. The New Ireland Fund earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned news headlines about the financial services provider an impact score of 45.0473493496562 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days. IrishCoin (CURRENCY:IRL) traded down 4.5% against the U.S. dollar during the one day period ending at 20:00 PM ET on June 22nd. In the last week, IrishCoin has traded 7.3% higher against the U.S. dollar. IrishCoin has a total market capitalization of $229,642.00 and $26.00 worth of IrishCoin was traded on exchanges in the last 24 hours. One IrishCoin coin can now be bought for about $0.0065 or 0.00000107 BTC on exchanges. ResMed Inc., incorporated on March 31, 1994, is a holding company. The Company, through its subsidiaries, designs, manufactures and markets equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. The Company develops a range of products for sleep-disordered breathing and other respiratory disorders, including airdevices, informatics solutions, diagnostic products, mask systems, headgear and other accessories. The Company owns interest in Inova Labs, Inc., a medical device company specializing in the development and commercialization of oxygen therapy products. The Company holds interest in Brightree LLC, a provider of business management and clinical software applications for the post-acute care industry. The Company's manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States. Its major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden. Next, two years ago, he picked "Five Stocks for April the Giraffe," the Washington Zoo favorite who was live-streamed giving birth to baby Tajiri. Those were Axon Enterprise (NASDAQ:AAXN), Grupo Aeroportuario del Pacífico (NYSE:PAC), ResMed (NYSE:RMD), Intuitive Surgical, and Live Nation (NYSE:LYV). The first letters of their tickers spell out A-P-R-I-L, and David and senior analyst Brian Feroldi will let us know if their returns should put a spring in your step. In related news, insider Robert Andrew Douglas sold 4,193 shares of the business’s stock in a transaction on Monday, December 17th. The stock was sold at an average price of $112.56, for a total value of $471,964.08. Following the completion of the sale, the insider now directly owns 89,605 shares in the company, valued at approximately $10,085,938.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James Hollingshead sold 5,893 shares of the business’s stock in a transaction on Tuesday, November 27th. The shares were sold at an average price of $105.52, for a total value of $621,829.36. Following the completion of the sale, the insider now owns 75,121 shares of the company’s stock, valued at $7,926,767.92. The disclosure for this sale can be found here. Insiders sold a total of 53,633 shares of company stock valued at $5,728,098 over the last 90 days. 1.24% of the stock is currently owned by corporate insiders. ResMed Company Profile ResMed (NYSE:RMD) Q2 2019 Earnings Conference CallJan. 24, 2019 4:30 p.m. ET Operator Get a free copy of the Zacks research report on ResMed (RMD) For more information about research offerings from Zacks Investment Research, visit Zacks.comTop 10 Clean Energy Stocks To Buy For 2021: Panasonic Corporation (PCRFY)
Panasonic Corporation is engaged in the development of diverse electronics technologies and solutions. The Company operates through five segments: Appliances, Eco Solutions, AVC Networks, Automotive & Industrial Systems, and Other. The Appliances segment is engaged in the development, manufacture and sale of consumer electronics, air-conditioners, cold chain and devices. The Eco Solutions segment is engaged in development, manufacture and sale of lighting fixtures, lamps, wiring devices, solar photovoltaic systems, ventilation and air-conditioning equipment, air purifiers and nursing-care-related products. The AVC Networks segment is engaged in development, manufacture and sale of products, such as aircraft in-flight entertainment systems, personal computers, and social infrastructure systems equipment. The Automotive & Industrial Systems segment is engaged in the development, manufacture and sale of automotive products, energy products, industrial devices and factory solutions. Advisors' Opinion: Top 10 Clean Energy Stocks To Buy For 2021: ProQR Therapeutics N.V.(PRQR)
Top 10 Clean Energy Stocks To Buy For 2021: Cotiviti Holdings, Inc. (COTV)
Cotiviti Holdings, Inc. is a provider of analytics-driven payment accuracy solutions. The Company is focused primarily on the healthcare sector. The Company operates through two segments: Healthcare, and Global Retail and Other. Through its Healthcare segment, the Company offers prospective and retrospective claims accuracy solutions to healthcare payers in the United States. The Company also provides analytics-based solutions unrelated to its healthcare payment accuracy solutions in the United States. Through its Global Retail and Other segment, the Company provides retrospective claims accuracy solutions to retailers primarily in the United States, Canada and the United Kingdom, as well as solutions that develop payment networks for a range of clients. The Company offers various solutions, such as prospective claims accuracy solutions, retrospective claims accuracy solutions and other services. Advisors' Opinion: Top 10 Clean Energy Stocks To Buy For 2021: Reaves Utility Income Fund(UTG)
Top 10 Clean Energy Stocks To Buy For 2021: Minerva Neurosciences, Inc(NERV)
Top 10 Clean Energy Stocks To Buy For 2021: Iridium Communications Inc(IRDMB)
Top 10 Clean Energy Stocks To Buy For 2021: Lincoln National Corporation(LNC)
Top 10 Clean Energy Stocks To Buy For 2021: New Ireland Fund, Inc. (IRL)
Top 10 Clean Energy Stocks To Buy For 2021: ResMed Inc.(RMD)
No comments:
Post a Comment